Clinical Trial Update: A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of HBI-8000 (tucidinostat) in combination with pembrolizumab for non-small cell lung cancer was terminated. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HBI-8000
• Tucidinostat (tucidinostat)

Snippet

Sponsor: HUYABIO International, LLC. | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-12-24